Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IncobotulinumtoxinA individualized high-dose treatment for severe spasticity after brain injury
2024-517668-51-01Phase 4Authorised
- Sponsor
- Dra. Nuria Gutierrez Dubón
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in Muscle spasm, sponsored by Dra. Nuria Gutierrez Dubón. Primary endpoint: Change in muscle tone on Ashworth scale at 6 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Muscle spasm
Beyond the preview
Go deeper on 2024-517668-51-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517668-51-01.